2024-03-29T09:37:53Zhttp://repisalud.isciii.es/oai/requestoai:repisalud.isciii.es:20.500.12105/109862023-10-09T11:22:04Zcom_20.500.12105_2109com_20.500.12105_2052com_20.500.12105_2051col_20.500.12105_2110
00925njm 22002777a 4500
dc
García-Romero, N
author
Palacín-Aliana, I
author
Madurga, R
author
Carrión-Navarro, J
author
Esteban-Rubio, Susana
author
Jiménez, B
author
Collazo, A
author
Pérez-Rodríguez, F
author
Ortiz de Mendivil, A
author
Fernández-Carballal, C
author
García-Duque, S
author
Diamantopoulos-Fernández, J
author
Belda-Iniesta, Cristobal
author
Prat-Acín, R
author
Calvo, E
author
Ayuso-Sacido, A
author
Sánchez-Gómez, Pilar
author
2020-06-22
Glioblastoma (GBM) is one of the most aggressive and vascularized brain tumors in adults, with a median survival of 20.9 months. In newly diagnosed and recurrent GBM, bevacizumab demonstrated an increase in progression-free survival, but not in overall survival.
We conducted an in silico analysis of VEGF expression, in a cohort of 1082 glioma patients. Then, to determine whether appropriate bevacizumab dose adjustment could increase the anti-angiogenic response, we used in vitro and in vivo GBM models. Additionally, we analyzed VEGFA expression in tissue, serum, and plasma in a cohort of GBM patients before and during bevacizumab treatment.
We identified that 20% of primary GBM did not express VEGFA suggesting that these patients would probably not respond to bevacizumab therapy as we proved in vitro and in vivo. We found that a specific dose of bevacizumab calculated based on VEGFA expression levels increases the response to treatment in cell culture and serum samples from mice bearing GBM tumors. Additionally, in a cohort of GBM patients, we observed a correlation of VEGFA levels in serum, but not in plasma, with bevacizumab treatment performance.
Our data suggest that bevacizumab dose adjustment could improve clinical outcomes in Glioblastoma treatment.
BMC Med . 2020 Jun 22;18(1):142.
1741-7015
http://hdl.handle.net/20.500.12105/10986
32564774
10.1186/s12916-020-01610-0
1741-7015
BMC medicine
Bevacizumab dose adjustment to improve clinical outcomes of glioblastoma.